Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

• Published in: Drugs & aging 2024-04, Vol.41 (4), p.357-366
• Main Authors: Ide, Joshua, Shoaibi, Azza, Wagner, Kerstin, Weinstein, Rachel, Boyle, Kathleen E., Myers, Andrew
• Format: Article
• Language: English
• Subjects: Accountability; Angina pectoris; Anti-inflammatory agents; Arthritis; Asthma; Cardiovascular disease; Chronic illnesses; Chronic pain; Comorbidity; Data models; Edema; Enzymes; Geriatrics/Gerontology; Health care policy; Health insurance; Heart attacks; Heart failure; Hypertension; Informatics; Internal Medicine; Ischemia; Medical personnel; Medicare; Medicine; Medicine & Public Health; Musculoskeletal diseases; Nonsteroidal anti-inflammatory drugs; Original; Original Research Article; Osteoarthritis; Pain management; Patients; Pharmacology/Toxicology; Pharmacotherapy; Prescription drugs; Review boards; Side effects
• ISSN: 1170-229X; 1179-1969
• DOI: 10.1007/s40266-024-01108-x

Background Osteoarthritis (OA) is a major cause of chronic pain. Non-steroidal anti-inflammatory drugs (NSAIDs) are analgesics commonly used for musculoskeletal pain; however, NSAIDs can increase the risk of certain adverse events, such as gastrointestinal bleeding, edema, heart failure, and hypertension. Objective The objective of this study was to characterize existing comorbidities among patients with OA. For patients with OA with and without a coexisting medical condition of interest (CMCOI), we estimated the prevalence of prescribing and dispensing NSAIDs pre-OA and post-OA diagnosis. Methods Data from three large administrative claims databases were used to construct an OA retrospective cohort. Databases leveraged were IBM MarketScan Medicare Supplemental Database (MDCR), IBM MarketScan Commercial Database (CCAE), and Optum’s de-identified Clinformatics ® Data Mart Database (Optum CDM). The OA study population was defined to be those patients who had an OA diagnosis from an inpatient or outpatient visit with at least 365 days of prior observation time in the database during January 2000 through May 2021. Asthma, cardiovascular disorders, renal impairment, and gastrointestinal bleeding risks were the CMCOI of interest. Patients with OA were then classified as having or not having evidence of a CMCOI. For both groups, NSAID dispensing patterns pre-OA and post-OA diagnosis were identified. Descriptive analysis was performed within the Observational Health Data Sciences and Informatics framework. Results In each database, the proportion of the OA population with at least one CMCOI was nearly 50% or more (48.0% CCAE; 74.4% MDCR; 68.6% Optum CDM). Cardiovascular disease was the most commonly observed CMCOI in each database, and in two databases, nearly one in four patients with OA had two or more CMCOI (23.2% MDCR; 22.6% Optum CDM). Among the OA population with CMCOI, NSAID utilization post-OA diagnosis ranged from 33.0 to 46.2%. Following diagnosis of OA, an increase in the prescribing and dispensing of NSAIDs was observed in all databases, regardless of patient CMCOI presence. Conclusions This study provides real-world evidence of the pattern of prescribing and dispensing of NSAIDs among patients with OA with and without CMCOI, which indicates that at least half of patients with OA in the USA have a coexisting condition. These conditions may increase the risk of side effects commonly associated with NSAIDs. Yet, at least 32% of these patients were prescr